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Short title: The role of homeoprotein Six1 in hepatocellular carcinoma 
 
 
Key words: Hepatocellular carcinoma, homeoprotein Six1, short hairpin RNA (shRNA) 
interference, metastasis, cDNA microarray. 
 
 
Abbreviations: HCC, hepatocellular carcinoma; pTNM, pathologic tumor metastasis; 
shRNA, short hairpin RNA; sqRT-PCR, semi-quantitative RT-PCR. 
 
 
Journal category: Cancer Cell Biology 
 
 
Novelty and impact: We firstly demonstrated that suppression of homeoprotein Six1 led 
to in vitro and in vivo decreases of tumorigenicity and metastatic ability of hepatocellular 
carcinoma (HCC). We believe that these findings are indispensible, in part, for understanding 
the carcinogenesis and metastasis of HCC and for development of therapeutic strategy for 
treatment of HCC.  
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Abstract 
 
We previously demonstrated that overexpression of homeoprotein Six1 in hepatocellular 
carcinoma (HCC) patients is associated with venous infiltration, advanced pathologic tumor 
metastasis (pTNM) stage and poor overall survival rate 1. In this study, short hairpin RNA 
(shRNA) interference approach was used to suppress the expression of Six1 in a metastatic 
HCC cell line MHCC97L. Stable transfectant MHCC97L-shSix1 carrying Six1 specific 
shRNA plasmid was established to downregulate Six1 expression to about 40% compared to 
MHCC97L-Control. In vitro functional assays demonstrated that the growth rate and 
proliferation ability of MHCC97L-shSix1 cells were markedly decreased. Moreover, 
significant decrease of cell motility and invasiveness were observed in MHCC97L–shSix1 
cells. Data from in vivo xenograft tumorigenesis model demonstrated that the size of tumor in 
MHCC97L-shSix1 group was dramatically reduced. Experimental and spontaneous 
metastasis models indicated that targeting Six1 suppression noticeably reduced the pulmonary 
metastasis in MHCC97L-shSix1 group. To identify Six1-regulated targets, cDNA microarray 
was employed to compare the expression profiles of MHCC97L-Control and 
MHCC97L-shSix1 cells. Twenty-eight down-regulated and 24 up-regulated genes with 
known functions were identified in MHCC97L-shSix1. The functions of these target genes are 
involved in diverse biological activities. Our data suggest that Six1 may be involved in 
regulation of proliferation and invasiveness of HCC; thus targeting suppression of Six1 is a 
viable option for treating HCC patients.  
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Introduction 
 
Hepatocellular carcinoma (HCC) is one of the most malignant tumors in the world, causing 
more than 600 000 deaths per year 2. Surgical treatments in terms of hepatic resection and 
orthotopic liver transplantation are frontline treatments for HCC, but the long-term 
disease-free survival remains unsatisfactory 3, 4. Tumor recurrence and metastases are the 
major causes of death in HCC patients after surgical treatments 5, 6, indicating the necessity of 
developing new therapeutic strategies targeting at tumor recurrence and metastases in HCC. 
Up to now, the molecular mechanisms of HCC metastasis remain unclear; hence identification 
and characterization of novel metastasis-associated genes are indispensable for development 
of effective treatment of HCC patients.  
Homeoprotein Six1 belongs to a subfamily of the Six family of homeodomain-containing 
transcription factors that shares a lysine within the DNA-binding helix of the homeodomain 7, 
8
. Six1, located at 14q23 of the chromosome is involved in early developments of diverse 
organs such as the brain, ear, eye, muscle and kidney 8-12. Alteration of Six1 expression takes 
place in human breast cancer, Wilms’ cancer, ovarian cancer and rhabdomyosarcoma, 
indicating its possible contributions in the tumorigenicity of different cancers 13-16. Six1 is 
also regarded as an important metastatic regulator in cancers. For example, overexpression of 
Six1 occurs in a large percentage of primary cancers, and strongly correlates with breast 
lesions 15. Six1 elevated in breast cancer promotes progression of breast cancer 17. Six1 also 
plays a substantial role in regulating the metastatic ability of rhabdomyosarcoma 13. The 
impact of Six1 on promoting tumorigenesis and metastasis of multiple cancers therefore 
impelled us to study the property of Six1 in HCC. We previously found that Six1 protein is 
specifically overexpressed in tumor tissues rather than non-tumor tissues of HCC patients. 
Overexpression of Six1 protein is significantly associated with venous infiltration, advanced 
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pathologic tumor metastasis (pTNM) stage and poor overall survival of HCC patients after 
surgical resection 1. Also, in vitro gene expression analysis found that Six1 protein is 
specifically expressed in metastatic HCC cells but not in non-metastatic HCC cells 1.  
In the present study, we suppressed the expression of Six1 in a metastatic HCC cell using 
short hairpin RNA (shRNA) interference technique to study the possible roles of Six1 in 
proliferative and metastatic abilities of HCC through in vitro and in vivo functional assays. 
Furthermore, cDNA microarray approach was employed to identify possible downstream 
targets of Six1 shedding some light on the regulation mechanism via in HCC.
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Material and methods 
Cell lines 
A human metastatic HCC cell line MHCC97L was a gift from Liver Cancer Institute & 
Zhongshan Hospital of Fudan University, Shanghai, People of Republic of China 18. The cell 
was cultured in DMEM high glucose medium (Gibco) with 10% fetal bovine serum (FBS, 
Gibco) and 1% penicilium and streptomycin in a 37oC incubator supplied with 5% CO2.  
 
Establishment of stable shRNA transfectant 
Oligonucleotide (CCAGCTCAGAAGAGGAATT) targeting Six1 gene was cloned into 
pGE-1 shRNA expression vector (Stratagene) according to manufactory’s instruction, 
designated pGE-1-shSix1. The sequence of pGE-1-shSix1 was confirmed by both enzymatic 
cutting with BamHI and XbaI and sequencing reaction using 5’ sequencing primer: 5’ 
CGTCGATTTTTGTGATGCTCGTCAG 3’. Control shRNA vector (Stratagene) and 
pGE-1-shSix1 were transfected into MHCC97L and under G418 selection for 2 weeks. 
MHCC97L-shSix and MHCC97L-Control represent cell lines stably transfected with 
pGE-1-shSix1 and control shRNA vector respectively. 
 
Reverse transcription-polymerase chain reaction (RT-PCR) 
Total RNA was extracted by using RNeasy Mini Kit (Qiagen). Each cDNA was 
synthesized from 1µg of total RNA using High capacity cDNA Kit (Applied BioSystems) 
under the condition of 25oC for 5 minutes following by 37oC for 2 hours. PCR reaction for 
Six1 gene was performed using Taq PCR kit (Promega) under the following PCR cycles: 
95oC for 5 minute, 30 cycles of 95oC for 1 minute, 57oC for 1 minute and 72oC for 1 minute. 
Amplification of 18S ribosomal RNA was used as an internal control. PCR products were 
visualized by 2% agarose gel electrophoresis stained with ethidium bromide. Primers sets 
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used were as follows: for Six1, sense AAG GAG AAG TCG AGG GGT GT, antisense TGC 
TTG TTG GAG GAG GAG TT; for 18S ribosomal RNA, sense CTC TTA GCT GAG TGT 
CCC GC, antisense. CTG ATC GTC TTC GAA CCT CC. 
 
Western blot analysis 
Proteins were extracted by 1X Lysis Buffer (Cell Signaling Technology). Protein extracts 
were separated by 12% SDS-PAGE and transferred to PDMF membrane (Millipore). After 
blocking with 5% non-fat milk for 1 hour, antibody, appropriately diluted, was hybridised 
with the membrane at 4oC over night. The membrane was washed 3 times with TBS/T each 
for 10 minutes and incubated with secondary antibody for 1 hour at room temperature. Protein 
signal was detected by ECL Plus system (GE Healthcare). Antibodies Six1 and β-Actin were 
purchased from Santa Cruz Biotechnology. 
 
Ultrastructural examination by scanning electron microscopy 
Cells grown on the cover-slips were fixed with 2.5% glutaraldehyde in 0.1 M sodium 
cacodylate-HCL buffer, pH 7.4, quenched with 0.1 M sucrose/cacodylate solution, washed in 
cacodylate buffer, and then fixed with 1% OsO4 in cacodylate buffer.  After cacodylate 
buffer wash, the samples were dehydrated through a graded series of ethanol washes, 
followed by critical point drying using a Bal-Tec CPD 030 critical point dryer (Bal-Tec AG, 
Liechtenstein).  Lastly, the samples were sputter-coated with a layer of gold (Bal-Tec 
SCD005 Sputter Coater, Bal-Tec AG) and visualized using Leica Cambridge Stereoscan 440 
SEM at an accelerating voltage of 12 kV 19. 
 
Cell proliferation assay 
One thousand of cells were seeded on 96-well plate and incubated in normal condition. 
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Cells were analysed by (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
(GE Healthcare) assay at 24-hour interval for 5 days. After incubation for 24 hours, cells were 
treated with 100µl of 5mg/ml of MTT solution for 4 hours at 37oC until crystals were formed. 
MTT solution was removed from each well and the crystals were dissolved with 100µl of 
DMSO. Color intensity was measured by Microplate Reader (Model 680, Bio-Rad) at 570nm. 
Each experiment consisted of five replications and at least four individual experiments were 
carried out 
 
Colony formation assay 
Five hundreds of cells were seeded onto 6-well plate and incubated in normal condition. 
After 2 weeks cultivation, cells were fixed by ice-cold methanol for 30 minutes and stained by 
Crystal violet for 10 minutes. Colonies (more than 50 cells) were counted directly on the plate. 
Statistical significant was calculated from each four independent experiments. 
 
Cell cycle analysis 
Cells (3x105) were seeded onto 6-well plate and synchronized in G0 by serum starvation 
for 3 days (DMEM without serum). Complete medium (DMEM plus 10% FBS) was replaced 
to stimulate the cell proliferation for the following 48 hours. At time 0, 24 and 48 hours 
interval, cells were trypsinized and fixed with 75% ice-cold ethanol for one hour. After 3 
times PBS washing, cells were stained with 1µg/ml of propidium iodide (PI) and 0.5µg/ml of 
RNase A at 37oC for 30 minutes. Cell cycle was analysed by flow cytometry. Each experiment 
was analysed in triplicate and at least three independent experiments were performed.   
 
Wound healing assay 
Cells (8x105) were seeded onto 24-well plate and incubated for 24 hours. Prior to 
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experiment, cells were treated with 10µg/ml mitomycin C (Sigma) for 3 hours. A 
straight-line-wound was made by scraping a 20µl-pipette tip across the cell monolayer. Cells 
were rinse with PBS and cultured in DMEM supplemented with varying concentration of FBS 
(1%, 5% and 10%) for 24 hours. The movement of cells towards the wound was captured 
under 100X magnification.  
 
Migration assay 
Migration ability of the cells were analysed by Polyethyleneterephthalate (PET)-based 
migration chamber with 8µm porosity (BD Labware, NJ). 5x104 cells were suspended in 500 
µl of serum-free DMEM and seeded into the migration chamber. The migration chamber was 
placed into a 24-well plate with 500µl of DMEM containing 10% FBS and incubated at 37oC 
with 5% CO2.  After 24 hours of incubation, cells on the upper surface of the chamber were 
scrapped out by a cotton swab. Cells migrated through the chamber were stained by 
hematoxylin and eosin (H & E) and subsequently counted under the microscope. At least 
three independent experiments were performed. 
 
Collagen type I assay 
Five microliters of cells (3x104 cells/ml) were mixed with 50µl of ice-cold rat tail collagen, 
type I (4.4mg/ml, BD Biosciences, MA). The mixture was plated as droplets in a 6-well plate 
until solidified; three droplets were made for each sample. The droplets in the plate were 
covered with DMEM medium containing 10% FBS and cultured for one week. Cell 
morphology was observed under microscope and captured under 400X magnification. One 
hundred colonies for each sample were counted and percentage of colonies that showing 
elongated morphology was calculated. 
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Immunofluorescent staining of F-actin 
Each of 3000 cells of MHCC97L-Control and MHCC97L-shSix1 were cultivated 
overnight on 8mm diameter Hydrophobic Printed Slide (Electron Microscopy Sciences). The 
cells were subjected for serum-starvation for 2 days. Induction of F-actin was performed by 
incubating the cells with 0.01µM lysophosphatidic acid (LPA) for 1 hour. The cells were 
washed with PBS buffer, fixed with 4% formaldehyde dissolved in PBS for 10 minutes at 
room temperature and permeabilized for 15 minutes with 0.1% Triton X-100. The cells were 
blocked with 1% bovine serum albumin in PBS for 30 minutes and then incubated with 
1µg/ml FITC-phalloidin (Sigma-Aldrich) at 37oC overnight. After 3 washes in PBS, the cells 
were stained with DAPI at room temperature for 10 minutes. The cells were washed 3 times 
with PBS and mounted with FluorSave Reagent (Calbiochem). The slides were analyzed by 
an image analysis system (Eclipse E600, Nikon). 
 
In vivo tumorigenicity model 
Cells (2x106) were suspended in 150µl of saline and subcutaneously injected into each 
nude mouse. The tumor size and body weight were measured for every 5 days. After 6 weeks, 
the mice were sacrificed and the tumors were harvested for further analysis. Six mice were 
recruited for each of the experimental group. Volume of the tumor was calculated as follows: 
tumor volume (cm3) = 1/2 x larger size x smaller size2.   
 
In vivo experimental and spontaneous metastasis models 
In vivo experimental metastasis model was established by injection of 2x106 cells 
suspended in 100µl of saline into the tail vein of nude mice. The in vivo spontaneous 
metastasis model was established in an orthotopic nude mice liver cancer model. Firstly, 
2x106 cells were subcutaneously injected into the left flank of the nude mice. The 
subcutaneous tumor tissues were then harvested once the tumor size reached 1cm3. It was cut 
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into about 1mm3 pieces and orthotopically implanted into the left lobes of the livers of 
another groups of nude mice 20. All mice were fed in standard condition with weight 
monitoring and sacrificed after 6-week incubation. Volume of the tumor was calculated as 
follows: tumor volume (cm3) = length x width x thickness. Liver and lung tissues were fixed 
by 10% formalin solution and subsequently analyzed by H & E staining. 
 
cDNA microarray analysis 
Genome-wide expression profile was analyzed by gene chip system Human U133 Plus 2.0 
(Affymetrix Inc. Santa Clara, CA). RNA quality control, sample labeling, GeneChip 
hybridization and data acquisition were performed at the Genome Research Centre, The 
University of Hong Kong. Total RNA was extracted from cells using RNeasy mini Kit 
(Qiagen). The quality of total RNA was checked by the Agilent 2100 bioanalyzer. The RNA 
was then amplified and labeled with MessageAmp II-Biotin Enchanced Single Round aRNA 
Amplification Kit (Ambion Inc., Texas). In brief, double-stranded cDNA was generated by 
reverse transcription from 1ug of total RNA with an oligo(dT) primer bearing a T7 promotor. 
The double strand cDNA was used as a template for in vitro transcription to generate 
biotin-labeled cRNA. After fragmentation, 15ug of cRNA was hybridized to the GeneChip 
array for 16 hours. The GeneChips were washed and stained using the GeneChip Fluidics 
Station 400 (Affymetrix Inc.) and then scanned with the GeneChip Scanner 3000 (Affymetrix 
Inc.). The experiment was performed twice. To compare the gene expression pattern between 
MHCC97L-Control and MHCC97L-shSix1, hybridization intensity between these 2 samples 
was normalized by Affymetrix global scaling method (Affymetrix Inc.). Genes with 2-fold 
difference, either increased or decreased, were selected for further confirmation by SYBR 
Green real-time PCR. 
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Confirmation of cDNA microarray data by SYBR green real-time RT-PCR 
Each 1µg of total RNA from MHCC97L-Control and MHCC97L-shSix1 cell lines was 
used to synthesize 22µl of cDNA using the High capacity cDNA Kit (Applied Biosystems, 
Foster City, CA). PCR analysis of each of the target gene was carried out in the following 
PCR mixture: 1µl of cDNA, 10µl of 2X Power SYBR Green PCR Master Mix (Applied 
Biosystems), 0.1µl of 10mM forward primer, 0.1µl of reverse primer and 8.8µl of distilled 
water. Primers for target genes are listed in Table I. Real-time PCR was carried out in a 7700 
Sequence Detection Instrument (Applied Biosystems) using the following thermal cycling 
profile: 95oC 1 minute, followed by 40 cycles of amplification (95oC 15 seconds, 60oC 4 
minutes). Analysis of dissociation curve for each pair of primers was conducted to examine 
the specificity of each PCR product. 
 
Statistical analysis 
Statistical analysis was carried out using SPSS 16.0 for Windows (SPSS Inc., IL).  
Two-tailed Student’s t test was used for analysis of continuous variables. P < 0.05 was 
considered to be statistically significant. 
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Results 
Suppression of Six1 expression by shRNA 
MHCC97L, a HCC cell line with metastatic potential to lung 18, overexpresses Six1 gene 
compared with other non-metastatic HCC cells 1. To investigate the role of Six1 in HCC 
metastasis, MHCC97L was transfected with DNA based Six1-specific shRNA plasmid 
(pGE-1-shSix1) and control plasmid (pGE-1-Control). The expression level of Six1 gene was 
suppressed by more than 2-folds in MHCC97L-shSix1 cell, both in mRNA (Fig. 1a) and 
protein (Fig. 1b) levels, compared to MHCC97L-control cell. Microscopically, the 
morphology of MHCC97L-shSix1 was changed to a rounder and more compressed shape 
compared with MHCC97L-Control (Fig. 1c). Under electron microscope (EM) analysis, 
MHCC97L-shSix1 displayed less numbers of extracellular “hair-like” connection fibres 
(lamellipodia formation) compared to MHCC97L-Control (Fig. 1d).  
 
Effect on cell proliferation and colony formation 
To investigate the effect of Six1 suppression on cell growth, MTT assay was employed to 
analyse the growth rate of MHCC97L-shSix1 and MHCC97L-Control for 5 days. Compared 
with MHCC97L-Control, MHCC97L-shSix1 exhibited slower growth rate and reached 2-fold 
difference on day 4 (Fig. 2a). Statistical analysis, by t-test, showed significant difference 
between 2 groups on day 2, 3, 4 and 5 (P < 0.01). Moreover, the number of colony formed in 
MHCC97L-shSix1 were significantly less than that in MHCC97L-Control (23 vs 108 in 
average, p=0.000, Fig. 2b). 
 
Effect on cell cycle 
To examine the effect of Six1 suppression on the cell cycle, DNA content of 
MHCC97L-shSix1 and MHCC97L-Control was analyzed by FACS using propidium iodide 
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(PI) staining. The cells were subjected to serum starvation for 3 days for synchronization of 
the cells in G0 phase, followed by re-supplementation of 10% serum for 2 days. The 
percentage of G2/M phase of MHCC97L-shSix1 were consistently higher than that of 
MHCC97L-Control on day 0, 1 and 2 (Fig. 3a). These results demonstrated that suppression 
of Six1 expression leads to a delay in G2/M transition (Fig. 3b). 
 
Effect on cell motility and invasion 
To investigate the effect of Six1 suppression on cell motility, three common methods 
including wound healing assay, migration assay and collagen type I invasion assay were 
performed on MHCC97L-Control and MHCC97L-shSix1 cells. Wound healing assay at 24 
hours after the creation of straight wound line showed that the wound in MHCC97L-Control 
almost recovered while the wound in MHCC97L-shSix1exhibitted only slight improvement 
(Fig. 4a). It was estimated that the wound-healing ability of MHCC97L-shSix1 was at least 
2-fold less than that of the MHCC97L-Control after 24 hours. Consistent results were 
observed at different serum concentrations. Migration assay showed that the number of 
migrated MHCC97L-shSix1 cells after 24 hours were about 50% less than that of 
MHCC97L-Control (69 vs 143 migrated cells in average, P=0.000, Fig. 4b). Using three 
dimensional collagen type I invasion assay, it was found that less number of 
MHCC97L-shSix1 cells grew inside the collagen gel and exhibited an elongated or scattered 
patterns compared with MHCC97L-Control (P=0.000, Fig. 4c). The above results 
demonstrated that down-regulation of Six1 gene suppressed the motility and invasiveness of 
metastatic HCC cells. 
 
Effect on distribution of F-actin  
Phalloidin staining of MHCC97L-Control after LPA stimulation showed that F-actin was 
evenly distributed all over the cells (Fig. 5). While in MHCC97L-shSix1, F-actin expression 
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was suppressed leading to decrease in stress fiber polymerization. This data demonstrated that 
suppression of Six1 expression decreases F-actin polymerization 
 
Effect on in vivo tumorigenicity  
The tumor growth rate was significantly delayed in MHCC97L-shSix1 group compared to 
MHCC97L-Control group at all time points (Figs. 6a and 6b). At day 30, the tumor size in 
MHCC97L-Control group was about 5-fold of the tumor size in MHCC97L-shSix1 group 
(1.71cm3 vs 0.36cm3 in average, p=0.000). The body weight in these two groups was similar 
(data not shown). Western blot analysis of subcutaneous xenografts showed that the level of 
Six1 protein in MHCC97L-shSix1 xenograft was also lower than in MHCC97L-Control 
xenograft (Fig. 6c). 
 
Effect on in vivo metastasis  
We performed experimental and spontaneous metastasis models to evaluate the effect of 
Six1 suppression on metastatic behaviours of MHCC97L cell line. For the experimental 
metastasis model, 6 weeks after inoculation, 3 of 7 (42.9%) mice were found to have 
pulmonary metastasis by H&E staining in MHCC97L-Control group (Fig. 7a), while there is 
no pulmonary metastasis in MHCC97L-shSix1 group. No liver tumor was found in both 
groups (Table II). However, the difference between these two groups was statistically 
insignificant (Table II). 
For the spontaneous metastasis model, 6 weeks after the implantation, it was found that 
less liver tumor formed in MHCC97L-shSix1 group (6 of 8, 75%) compared to that of the 
MHCC97L-Control group (8/8, 100%). Moreover, the average size of liver tumor in 
MHCC97L-shSix1 group was noticeably smaller than that of the MHCC97L-Control group 
(Fig. 7b and Table II). Furthermore, the aggressive phenotype of tumor was attenuated in 
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MHCC97L-shSix1 group compared to MHCC97L-Control group (Fig. 7b). Lastly, H & E 
staining of lung section (Fig. 7b) revealed that more than 60% (5 of 8) of mice in 
MHCC97L-Control group showed pulmonary metastasis while no pulmonary metastasis case 
was developed in MHCC97L-shSix1 group (Table II). Statistical analysis indicated that both 
tumor volume (p=0.000) and metastasis potential (p=0.026) in MHCC97L-shSix1 group were 
significantly reduced compared to MHCC97L-Control group (Table II). 
 
Identification of downstream targets of Six1 
To find out the genes under the regulation of Six1, gene expression profiles of 
MHCC97L-shSix1 were compared with MHCC97L-Control using cDNA microarray analysis. 
A total of 61 down-regulated and 59 up-regulated differential targets were found in 
MHCC97L-shSix1 compared to that in MHCC97L-Control. After screening out those 
unknown genes and EST sequences, a total of 28 down-regulated and 24 up-regulated genes 
with known functions were identified (Tables III and IV). A summary for down-regulated and 
up-regulated genes was generated based on their functions (Fig. 8). 
To validate the cDNA microarray results, 15 either down-regulated or up-regulated genes 
that have higher fold changes among samples were selected and confirmed by SYBR green 
real-time semi-quantitative RT-PCR (sqRT-PCR). Dissociation curve for each gene was tested 
to make sure that only a specific PCR product indicated by production of a single peak was 
generated for each pair of primers (data not showed). Otherwise, new pairs of primers were 
redesigned and retested. The Ct value for each gene was normalized with the Ct value of 18S 
primers. For down regulated genes, most of the results from sqRT-PCR were consistent with 
the findings from cDNA microarray analysis (Table III). For up-regulated genes, sqRT-PCR 
results showed higher fold changes than the microarray analysis (Table IV).  
Genes differentially expressed upon suppression of Six1 gene were found to be involved in 
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diverse physiological roles. Among those down-regulated genes, most of the genes were 
involved in signal transduction, protein trafficking and metabolism (Fig. 8). Moreover, several 
oncogenes such as YWHAH, CD46, CRKII and ADAM 10 were down-regulated. While 
up-regulation of genes involved in transcription regulation, cell growth, transport, immunity 
and signal transduction (Fig. 8).  
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Discussion 
Several lines of evidence suggest that Six1 is deregulated in various mammalian cancers 
and overexpression of Six1 lead to an increase of malignancy of tumors subsequently causing 
higher mortality rate of cancer patients 13, 15, 16. In HCC, overexpression of Six1 protein is 
significantly correlated with advanced pTNM stage, venous infiltration and poor overall 
survival 1. To further investigate the possible role of Six1 in HCC, we employed shRNA 
technology to suppress the expression of Six1 gene in a metastatic HCC cell line MHCC97L 
which overexpresses Six1 protein compared with other non-metastatic HCC cell lines 1. We 
generated stable clone (MHCC97L-shSix1) in which Six1 expression was suppressed over 
50% in both mRNA and protein levels compared to MHCC97L-Control. In vitro assays 
showed that suppression of Six1 expression significantly reduced the growth rate and the 
ability of forming colonies of MHCC97L, suggesting that Six1 may play an essential role on 
tumor proliferation. In vivo xenograft tumorigenesis model also supported that inhibition of 
Six1 expression hindered the growth rate of HCC in nude mice. In breast cancer, 
overexpression of Six1 promotes tumorigenesis and progressiveness of the tumor by targeting 
cyclin A1 expression 17. Moreover, overexpression of Six1 in ovarian cancer promotes the 
proliferative phenotype of the tumor cell 16. All these evidences suggested that Six1 may 
participate in oncogenic regulation in multiple cancers. 
Deregulation of cell cycle control is one of the characteristics of cancers. Abrogation of 
G2/M phase arrest induced by DNA damage is a mechanism of cancer cells to resist therapies 
such as radiation and chemotherapy. Six1 has been identified in the late S phase in breast 
cancer and its overexpression can abrogate DNA damage-induced G2 cell cycle arrest 15. In 
our present study, cell cycle analysis showed that suppression of Six1 expression in 
MHCC97L resulted in a delay in G2/M transition suggesting that Six1 may function in G2/M 
phase regulation in HCC. An arrest in G2/M phase can disrupt cell cycle progression and can 
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be attributed to the observed decrease in growth rate of MHCC9L-shSix1 cells with respect to 
MHCC97L-Control cells. The role of Six1 on G2/M phase regulation of HCC is thus 
beneficial to understand the abnormal progression of cell cycle and chemoresistance of HCC. 
The mechanism of Six1 in G2/M regulation and the relationship with cell cycle regulators in 
HCC remains to be determined. 
MHCC97L is a metastatic HCC cell line which can metastasize to lung from liver 21. Our 
data showed that suppression of Six1 expression in this cell line resulted in inhibition of its in 
vitro metastatic activities including wound-healing, migration and invasion abilities. 
Decreases in lamellipodia formation on the cell surface and intracellular stress fiber 
polymerization were observed in MHCC97L-shSix1 indicating that suppression of Six1 
expression could reduce the motility of the cell. Furthermore, a significant suppression of 
lung metastasis was observed in MHCC97L-shSix1 group in the in vivo spontaneous 
metastasis model. The in vivo metastasis rate of MHCC9L-Control in spontaneous metastasis 
model was 62.5% in our study (Table II) which is higher than that of the original MHCC97L 
(40%) claimed by Li et al, 21. This may be due to accumulative genetic changes leading to 
increased metastatic potential of this cell line. Altogether, these results implied that the 
function of Six1 may be linked to metastatic ability of HCC. Therefore alteration of Six1 
expression may influence certain step(s) of the metastatic pathway of HCC. In 
rhabdomyosarcoma, in vitro and in vivo experiments indicated that changes in Six1 
expression can alter the metastatic potential of rhabdomyosarcoma cell lines. Forced 
up-regulation of Six1 overexpression can increase the metastatic potentials of the poorly 
metastatic rhabdomyosarcoma cell lines while suppression of Six1 expression can reduce the 
metastatic potential of the highly metastatic rhabdomyosarcoma cell line 13. Metastasis is one 
of the major causes of death in HCC patients due to malignant status of the tumor and no 
effective treatment for these patients. An increasing number of metastasis-associated genes 
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were identified in HCC in recent years 22, 23. Unfortunately, the regulation mechanism of 
metastasis of HCC is still not very clear even to this date. . Therefore, identification and 
characterization of novel metastasis-associated genes are crucial for understanding its possible 
mechanism and ultimate, for the development of an effective therapeutic strategy. Taken 
together, our results demonstrated that Six1 is undoubtedly involved in the progression and 
metastasis of HCC. Suppression of Six1 expression successfully hindered both tumorigenesis 
and metastasis of HCC suggested its potential therapeutic value in treatment of HCC. 
Six1 can activate several genes during development and more importantly, in cancers 24. 
Identification of downstream targets of Six1 in HCC would provide better understanding on 
its regulation mechanism in HCC. With this in mind, cDNA microarray analysis was 
performed to identify differential genes in MHCC97-shSix1 compared to MHCC97L-Control. 
A total 120 differential genes were identified and finally 28 down-regulated and 24 
up-regulated genes with known functions were obtained. These differential genes function 
involved in diverse biological activities such as signaling regulation, protein trafficking, 
transcription regulation and growth control, revealing that Six1 can activate multiple genes in 
HCC. In other cancers, Six1 can activate several oncogenes, such as Cyclin A1 in breast and 
ovarian cancers 16, 17 and c-Myc, Cyclin D1 as well as ezrin in rhabdomyosarcoma 25. Several 
tumor-associated genes were found to down-regulated in MHCC97L-shSix1 including 
YWHAH (or 14-3-3 eta), CD46, CRKII and ADAM 10 26-29, indicating that Six1 may regulate 
the expression of these oncogenes in HCC. The downstream targets of Six1 identified in HCC 
were different from other cancers suggested that the regulation mechanism of Six1 in HCC 
may be different from other cancers. Six1 may activate the expression of various genes 
involved in different biological functions that may probably take part in carcinogenesis and 
metastasis of HCC. The functions of these differential genes and their relationship with Six1 
are needed to be further characterized. 
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Our study demonstrated that suppression of Six1 led to decreases of tumorigenicity and 
metastatic ability of HCC suggesting its important therapeutic implications for future drug 
development and treatment of HCC.
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Figure legends 
 
FIGURE 1 - (a) RT-PCR and (b) Western blot analyses of Six1 gene among MHCC97L, 
MHCC97L-Control and MHCC97L-shSix1 cells.. Ribosomal RNA (18S) and beta-actin 
protein were use as internal control for RT-PCR and Western blot respectively. (c) 
Microscopic and (d) Scanning electron microscope examination of the morphologies of 
MHCC97L-Control and MHCC97L-shSix1 cells. 
 
FIGURE 2 - Proliferation characteristics of MHCC97L-Control and MHCC97L-shSix1 cells. 
(a) MTT assay of cells. (b) Colony formation assay.  *, p < 0.01. 
 
FIGURE 3 - Cell cycle analysis of MHCC97L-Control and MHCC97L-shSix1 cells for 2 
days. (a) Histogram of cell cycles. (b) Comparison of percentage of G2M phase between 
MHCC97L-Control and MHCC97L-shSix1. 
 
FIGURE 4 - Cell motility and invasion assays of MHCC97L-Control and MHCC97L-shSix1 
cells. (a) Wound healing assay after 24 hours in different serum concentration. Arrows 
indicate the gap between wound. (b) Migration assay after 24 hours. (c) Collagen type I assay 
after 1 week. *, P < 0.01. 
 
FIGURE 5 - F-actin staining of MHCC97L-Control and MHCC97L-shSix1 cells. 
 
FIGURE 6 - Xenograft tumorigenesity model between MHCC97L-Control and 
MHCC97L-shSix1 groups. (a) Representative subcutaneous xenografts generated in mice 
after 30-day inoculation. (b) Tumor size of subcutaneous xenografts measured with 5-day 
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interval. *, p < 0.01. (c) Western blot analysis of Six1 protein level between the subcutaneous 
tumor xenografts from MHCC97L-Control and MHCC97L-shSix1 groups. 
 
FIGURE 7 - (a) H & E staining of formalin fixed lung tissues from MHCC97L-Control and 
MHCC97L-shSix1 groups in experimental metastasis model. (b) Representative liver 
xenografts, H & E staining of liver tissues and lung tissues of MHCC97L-Control and 
MHCC97L-shSix1 groups in spontaneous metastasis model. Arrows indicate the formation of 
tumors in lung tissues. 
 
FIGURE 8 - Summary of differential genes in MHCC97L-shSix1 comparing with 
MHCC97L-Control. Number (s) followed each category indicates the number of genes found. 
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TABLE I - LIST OF PRIMERS FOR SYBR GREEN REAL-TIME sqRT-PCR 
Gene Forward primer Reverse primer Size 
ADAM10 5’ GCAACATCTGGGGACAAACT 3’ 5’ TGGCCAGATTCAACAAAACA 3’ 110 bp 
ADRCE1 5’ AATGGTGAAGAAGGCACGTC 3’ 5’GCTCTCCGAGCCAGTGTTAC 3’ 108 bp 
ATF3 5’ TCTAGGCTGGAAGAGCCAAA 3’ 5’ CTGGTACCACCAGCTCCACT 3’ 104 bp 
CAMK2N1 5’ GATTCTTGTATGGCCAGGA 3’ 5’ GTGGATTCTGCCTCACC 3’ 109 bp 
CD46 5’ CGAGTGTCCCTTTCCTTCCT 3’ 5’ AAATGTTGGTGGCTCCTCAC 3’ 103 bp 
CGIP39 5’ CTGAGGTCCCTAGCTCGTTG 3’ 5’ GGGGTCATCCACTCTTGAAA 3’ 103 bp 
CHAC1 5’ CCTCGATCCTCTGCTCACTC 3’ 5’ TACAGGGCTCCTTCTCCTCA 3’ 114 bp 
COM1 5’ AAAGGTCGCACCAAGAGAGA 3’ 5’ CCTCGCTTCTTCCTCTCTGA 3’ 110 bp 
CRKII 5’ CCAATGCCTACGACAAGACA 3’ 5’ ACCTCGTTTGCCATTACACC 3’ 110 bp 
CTH 5’ TGAATGGCCACAGTGATGTT 3’ 5’ GGAGATGGAACTGCTCCAAG 3’ 108 bp 
DDIT3 5’ CAGAGCTGGAACCTGAGGAG 3’ 5’ CCATCTCTGCAGTTGGATCA 3’ 108 bp 
DNAJ9B 5’ AATGGCTACTCCCCAGTCAA 3’ 5’ CCGATTTTGGCACACCTAAG 3’ 110 bp 
DNMT3B 5’ CAAGACTCGAAGACGCACAG 3’ 5’ ATCTTCATCCCCTCGGTCTT 3’ 112 bp 
EIF1AX 5’ CGCAGGGGTAAGAATGAGAA 3’ 5’ TTGCTTCTAGCCGTCCATTT 3’ 112 bp 
Inhibin BE 5’ AGGGTAAGGGCTGTTGAGGT 3’ 5’ TGCCTCATTTTCCTGACTCC 3’ 111 bp 
MAPKAP 5’ TTTCATGCTGGCATTTTTCA 3’ 5’ CCGCAGATAGCACCATACCT 3’ 105 bp 
MEIS2e 5’ TGAGCAAGGGGATGGTTTAG 3’ 5’ ACTTTGGGGAAAATGCCTCT 3’ 111 bp 
NUPL1 5’ TTTTCAAACTGGGGAAAACG 3’ 5’ TTTCCATGATCACCCCAAAT 3’ 109 bp 
PELI1 5’ CCAAATGGCGATAGAGGAAG 3’ 5’ GCAGCCTGAGGAGTACAAGC 3’ 110 bp 
PGRMC1 5’ GCCTGGATAAGGAAGCACTG 3’ 5’ GCCCACGTGATGATACTTGA 3’ 119 bp 
POLR3K 5’ CAAGTGCTGCAATGCTCAGT 3’ 5’ TGCCAGCTAAGCATCTACCC 3’ 110 bp 
PPP1R15A 5’ GAGGAGGCTGAAGACAGTGG 3’ 5’ ATGCCATCATCATCATCCAA 3’ 110 bp 
RDH11 5’ GCAAGCTAGCCAACATCCTC 3’ 5’ GTGCCGAACCAGTTCAGATT 3’ 113 bp 
SESN2 5’ TACTTGCCATTCACCCATCA 3’ 5’ GAACTAGGATTCGGGCAACA 3’ 114 bp 
SLC4A4 5’ TCATGGATCGTCTGAAGCTG 3’ 5’ CACCTGCAGGAAAGTGAACA 3’ 110 bp 
STC2 5’ GGACAGAACCAAGCTCTCCA 3’ 5’ CTCTTGCTACCTCGCTCACC 3’ 111 bp 
TARDBP 5’ TACTCCCCCTACCCCTTTGT 3’ 5’ GTTCTCAGCCCATCAGCTTC 3’ 110 bp 
TIEG2 5’ GCCGAATCCATACACAAGGT 3’ 5’ GTAAACCATCCCCCTTCCAC 3’ 110 bp 
YWHAH 5’ GACCAGCAGGATGAAGAAGC 3’ 5’ TTGTGGCAAGGAAGAATCG 3’ 107 bp 
ZBTB43 5’ CCAGATGTGGCATGTGGTAG 3’ 5’ TACTGCTGCTTGGTGACTGG 3’  110 bp 
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TABLE II - SUMMARY OF XENOGRAFT METASTASIS MODELS 
  MHCC97L-Control MHCC97L-shSix1 P valuea  
      
Experimental metastasis model      
Liver metastasis  0/7 (0%) 0/8 (0%) NS  
Pulmonary metastasis  3/7 (42.9%) 0/8 (0%) NS  
      
Spontaneous metastasis model      
Liver tumor formed   8/8 (100%) 6/8 (75%) NS  
Tumor volume (cm3)  1.84 + 1.032 0.049 + 0.014 0.000  
Pulmonary metastasis  5/8 (62.5%) 0/8 (0%) 0.026  
      
Note: aNS, no significance. 
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TABLE III - SUMMARY OF DOWN-REGULATED GENES IN MHCC97L-shSix1 
Accession Gene name 
Fold change 
(Microarray) 
Fold changea 
(sqRT-PCR) Functions 
NM_003405 Tyrosine 3-monooxygenase-tryptophan 5- 
monooxygenase activation protein, eta polypeptide 
(YWHAH) 
-2.14 -2.92 Adapter protein implicated in the regulation of a large spectrum of both general 
and specialized signaling pathways 
AB097031 MAPK activating protein (MAPKAP) -3.35 -2.71 Involved in activation of MAPK signaling pathway 
NM_002389 CD46 -2.34 -2.7 A cofactor for complement factor I 
BC047523 Calmodulin 1, phosphorylase kinase, delta (CAMK2N1) -2.3 -2.67 It may mediate the control of a large number of protein kinases and phosphatases 
BC034238 Progesterone receptor membrane component 
1(PGRMC1)  
-2.14 -2.67 A receptor for progesterone 
NM_016823 v-crk avian sarcoma virus CT10 oncogene homolog 
(CRKII) 
-2.46 -2.21 Mediates attachment-induced MAPK8 activation, membrane ruffling and cell 
motility in a Rac-dependent manner. 
NM_016310 Polymerase (RNA) III polypeptide K (POLR3K) -2.14 -2.51 Functions in RNA synthesis 
NM_003759 Solute carrier family 4, sodium bicarbonate cotransporter, 
member 4 (SLC4A4) 
-2.14 -2.44 Involved in regulation of intracellular PH 
NM_016026 Retinol dehydrogenase 11 (RDH11) -2 -2.44 Exhibits an oxidoreductive catalytic activity towards retinoid 
NM_001110 ADAM metallopeptidase domain 10 (ADAM10) -2 -2.42 Responsible for the proteolytic release of several cell-surface proteins 
NM_020651 Pellino homolog 1 (PELI1) -2.14 -2.21 Scaffold protein involved in the IL-1 signaling pathway 
BC069196 SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily e, 
member 1 (ADRCE1) 
-2.46 -2.12 Involved in transcriptional activation and repression of select genes by chromatin 
remodeling 
NM_020149.1 TALE homeobox protein Meis2e (MEIS2E) -2 -2.0 A transcriptional factor 
AL079283.1 Eukaryotic translation initiation factor 1A, X-linked 
(EIF1AX) 
-2.64 -2.08 Involved in maximization of the rate of protein biosynthesis 
NM_007375.1 TAR DNA binding protein (TARDBP) -2 -2 Involved in the regulation of CFTR splicing 
NM_006667.2 Progesterone binding protein -2.14 UC A putative steroid membrane receptor 
NM_006827 Transmembrane emp24-like trafficking protein 10 -2 UC Involved in vesicular protein trafficking 
U07802 Butyrate response factor 2 (EGF-response factor 2) -2 UC A putative nuclear transcription factor most likely functions in regulating 
the response to growth factors 
AI346910 VAMP (vesicle-associated membrane 
protein)-associated protein A 
-2 UC Functions in vesicle trafficking, membrane fusion, protein complex 
assembly and cell motility 
AA885297 CD36 antigen (collagen type I receptor, 
thrombospondin receptor)-like 2 
-2.3 UC Participates in membrane transportation and the reorganization of 
endosomal/lysosomal compartment 
BF246917 Protein kinase, cAMP-dependent, regulatory, type 
II, alpha (PRKAR2A) 
-2.14 UC Regulates protein transport from endosomes to the Golgi apparatus and 
further to the endoplasmic reticulum (ER) 
AV725664 Phosphatidic acid phosphatase type 2B (PPAP2B) -2 UC Actively hydrolyzes extracellular lysophosphatidic acid and short-chain 
phosphatidic acid 
NM_006375.1 Cytosolic ovarian carcinoma antigen 1 (COVA1) -2 UC The encoded protein has two enzymatic activities: catalysis of 
hydroquinone or NADH oxidation, and protein disulfide interchange 
AW195360 Integral inner nuclear membrane protein -2 UC A membrane protein 
BF692332 Ribosomal protein S4, X-linked -2.3 UC Catalyzes protein synthesis 
L11372.1 Protocadherin 43 -2 UC Plays a critical role in the establishment and function of specific cell-cell 
connections in the brain 
BF061658 Transforming growth factor, beta 2(TGFB2) -2 UC Plays a role in regulation of cell growth and proliferation and may be 
involved in mesenchymal-epithelial cell interactions during development 
AW022607 Glyceronephosphate O-acyltransferase -2 UC Catalyzes the transesterification of dihydroxyacetone phosphate (DHAP) 
to form acyl-DHAP 
Note: aUC, un-confirmed by sqRT-PCR.     
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TABLE IV - SUMMARY OF UP-REGULATED GENES IN MHCC97L-shSix1 
Accession Gene name 
Fold change 
(Microarray) 
Fold changea 
(sqRT-PCR) Functions 
     
AF288391.1 Cell growth inhibiting protein 39  4.59 8.94 Related to growth inhibition 
BC005161.1 Inhibin BE 4.59 5.27 Inhibits the secretion of follitropin by the pituitary gland. 
NM_001902.1 Cystathionase (cystathionine gamma-lyase) (CTH) 2.64 4.9 Functions in amino-acid biosynthesis 
NM_024111.1 ChaC, cation transport regulator homolog 
1(CHAC1) 
3.48 4.848 Cation transport regulator 
BC000658.1 Stanniocalcin 2 (STC2) 2.14 4.32 Anti-hypocalcemic action on calcium and phosphate homeostasis 
AB066566.1 ATF3 mRNA for activating transcription factor 3 
delta Zip2 (ATF3) 
3.25 4.31 Represses transcription from promoters with ATF sites 
BF131886 Sestrin 2 (SESN2) 3.03 4.132 Involved in regulation of cell growth and survival 
AF135266.1 p8 protein homolog (COM1) 2.30 3.98 A structure protein 
NM_012328.1 DnaJ (Hsp40) homolog, subfamily B, member 9 
(DNAJB9) 
2.3 3.90 A co-chaperone with Hsp70 protein 
NM_014778.1 Nucleoporin like 1 (NUPL1) 2.64 3.84 Involved in regulation of protein trafficking 
BC003637.1 DNA-damage-inducible transcript 3 (DDIT3) 2.14 3.81 Negative regulator of transcriptional factors 
NM_006892.1 DNA (cytosine-5-)-methyltransferase 3 beta 
(DNMT3B) 
2.64 3.32 Involved in DNA methylation and development 
AA149594 TGFB inducible early growth response 2 (TIEG-2) 2 3.05 A transcriptional factor 
NM_014007.1 Zinc finger and BTB domain containing 43 
(ZBTB43) 
2.14 2.86 Involved in transcriptional regulation 
NM_014330.2 Protein phosphatase 1, regulatory inhibitor subunit 
15A (PPP1R15A) 
2 2.60 A growth arrest and DNA-damage-inducible protein 
M57731.1 Cytokine gro-beta 2 UC Cytokine 
NM_000565.1 Interleukin 6 receptor (IL6R) 3.03 UC Potent pleiotropic cytokine that regulates cell growth and differentiation 
and plays an important role in immune response 
M27968.1 Fibroblast growth factor 2 2 UC Implicated in diverse biological processes, such as limb and nervous 
system development, wound healing, and tumor growth 
AB052156.1 MAPK phosphatase-7 2.14 UC Negatively regulates MAPK activity 
AF202640.1 Orphan G-protein coupled receptor (GPRC5B) 2 UC Mediates the cellular effects of retinoic acid on the G protein signal 
transduction cascade 
J03580.1 Parathyroid hormone-like hormone 2.64 UC Regulates endochondral bone development and epithelial-mesenchymal 
interactions during the formation of the mammary glands and teeth 
AI268381 Regulatory solute carrier protein, family 1 2 UC Membrane-associated modulator of the sodium-glucose cotransport system 
AF031587.1 MIP-1 delta 2 UC Induces changes in intracellular calcium concentration in monocytes and is 
thought to act through the CCR1 receptor 
NM_001561.2 Tumor necrosis factor receptor superfamily, 
member 9 (TNFRSF9) 
4 UC Contributes to the clonal expansion, survival, and development of T cells 
 Note: aUC, un-confirmed by sqRT-PCR    
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